Workflow
IPI
icon
Search documents
6月广东核心CPI同比上涨0.3%
国家统计局广东调查总队近日发布上半年物价等数据。6月,受节假日假期结束、供给充足等因素影 响,广东居民消费价格指数(CPI)同比下降0.4%,降幅与5月持平,环比下降0.2%,降幅比5月扩大0.1个 百分点。扣除食品和能源价格的核心CPI同比上涨0.3%,涨幅较上月回落0.1个百分点。1—6月平均, CPI比上年同期下降0.4%。 从同比看,PPI同比下降1.8%,降幅与5月持平。其中,生产资料价格下降2.5%,降幅比5月收窄0.1个百 分点,影响工业生产者出厂价格总水平下降1.63个百分点;生活资料价格下降0.4%,降幅比5月扩大0.1 个百分点,影响工业生产者出厂价格总水平下降0.12个百分点。在PPI调查的38个大类行业中,同比指 数"11涨26降1平",行业上涨面为28.9%,比5月扩大2.6个百分点。 主要行业中,价格波动较大的有:文教、工美、体育和娱乐用品制造业价格上涨10.6%;黑色金属矿采 选业价格下降14.8%,石油、煤炭及其他燃料加工业价格下降13.1%,石油和天然气开采业价格下降 10.1%,黑色金属冶炼和压延加工业价格下降9.5%,化学纤维制造业价格下降7.0%。 从环比看,PPI下降 ...
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Globenewswire· 2025-07-09 11:50
Core Insights - Artelo Biosciences, Inc. presented preclinical data on its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, at the 35th Annual International Cannabinoid Research Society Symposium, demonstrating its potential to alleviate osteoarthritis (OA) pain [1][2][5] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and neurological disorders [7] - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [7] Product Development - ART26.12 is a first-in-class, non-opioid, non-steroidal analgesic drug candidate that has shown significant efficacy in alleviating OA pain in preclinical models [2][3] - The drug demonstrated comparable efficacy to naproxen, a commonly prescribed NSAID, without developing tolerance over a four-week chronic dosing period [3][5] - ART26.12's administration led to increased plasma levels of endocannabinoids 2-Arachidonoylglycerol (2-AG) and Oleoylethanolamide (OEA), which were positively correlated with pain relief [3] Safety Profile - ART26.12 may offer a safer alternative to NSAIDs, which are associated with gastrointestinal side effects in about one-third of patients and a five-fold increase in gastric ulcer complications [4] - The distinct pharmacological profile of ART26.12 suggests it could provide ongoing pain relief without the adverse effects commonly seen with NSAIDs [4][5] Research Collaboration - The research on ART26.12 was conducted in collaboration with Stony Brook University, highlighting the company's commitment to translational research [3][5] Market Context - Osteoarthritis affects approximately 606.9 million people globally, with over 32 million in the U.S., indicating a significant market opportunity for effective pain management solutions [9]
Il était une fois... la sérendipité | Sylvain ALLEMAND | TEDxSaclay
TEDx Talks· 2025-07-08 15:11
Oui, je suis journaliste et ce que j'aime absolument dans ce métier, c'est la possibilité d'interviewer des personnes d'horizon différents, de recueillir leurs histoires. Et s'il y a bien quelqu'un ce soir que j'aurais adoré interviewer, c'est Horas Wpul, l'écrivain anglais auquel on doit la notion de ses rendipités. Il l'a forgé en 1754 en désignant par là le fait de trouver par hasard quelque chose d'important qu'on avait pas cherché. Vous me direz pourquoi la sérendipité. C'est en référence à un très vie ...
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Globenewswire· 2025-06-24 12:30
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA) for a Phas ...
Io voglio essere un parassita (e altre verità che ho imparato) | Sara Ciafardoni | TEDxPutignano
TEDx Talks· 2025-06-16 15:41
[Musica] [Musica] [Applauso] Sono nata in un mondo che non aveva previsto uno spazio. per me, ma non fraintendetemi, non parlo di spazio fisico. C'era abbastanza area per respirare, abbastanza cielo da guardare ed, essendo stata probabilmente piccola così, avevo anche tutto tutto lo spazio per muovermi.Ma la verità è che la mia esistenza nasce da un paradosso. Dalla malattia è nata la vita. Mia mamma aveva scoperto da pochissimo di avere un tumore, uno di quelli difficili che ti scombussolano tutto.Fu segui ...
5月广东CPI同比下降0.4% PPI环比降幅收窄
Sou Hu Cai Jing· 2025-06-11 11:13
Group 1: Consumer Price Index (CPI) Analysis - In May 2025, Guangdong's Consumer Price Index (CPI) decreased by 0.4% year-on-year, maintaining the same decline as the previous month, and a month-on-month decrease of 0.1% compared to a 0.3% increase in the previous month, resulting in a fluctuation of 0.4 percentage points [1] - The average CPI for January to May 2025 was down 0.4% compared to the same period last year [1] - Factors influencing the CPI included a 4.0% increase in fresh fruit prices due to the arrival of lychee season and increased demand from warmer weather, and a 2.3% increase in aquatic product prices due to reduced market supply during the fishing ban and increased demand during holidays, collectively contributing approximately 0.15 percentage points to the CPI increase [1] Group 2: Producer Price Index (PPI) Analysis - In May 2025, Guangdong's Producer Price Index (PPI) decreased by 1.8% year-on-year, with the decline widening by 0.4 percentage points compared to the previous month, and a month-on-month decrease of 0.2% [1] - The average PPI for January to May 2025 was down 1.3% year-on-year [1] - The Industrial Producer Purchase Price Index (IPI) also saw a year-on-year decrease of 3.1% and a month-on-month decrease of 0.4% [1] - The decline in PPI was influenced by falling international crude oil prices, overcapacity in certain industries, and insufficient downstream market demand [1][2] - In the PPI survey of 38 major industries, 6 industries saw price increases, 26 experienced price declines, and 6 remained stable, indicating an industry price increase rate of 15.8% [2] - Specific industries affected included a 3.6% decrease in oil and gas extraction prices, a 3.0% decrease in petroleum, coal, and other fuel processing prices, and a 4.1% decrease in black metal mining prices due to reduced demand in the construction and real estate sectors [2]
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
Globenewswire· 2025-06-06 20:05
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning o ...
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Globenewswire· 2025-06-05 13:00
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company’s common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing ...
欧盟限制中国医疗器材进口,商务部:坚决反对,望欧方纠正错误做法
Huan Qiu Shi Bao· 2025-06-03 22:53
2024年4月24日,欧盟宣布对中国医疗设备领域公共采购在IPI下进行为期9个月的调查,成为IPI措施下 首起调查。当天,欧盟中国商会就发表声明主张,欧方启动调查应基于全面客观的事实。欧方对中国保 障内外资企业平等参与政府采购以及积极促进医疗领域招商对接的最新政策可能了解不足。 在6月2日最新发表的声明中,欧盟中国商会特别指出,一味追求所谓"市场平等"并不能脱离历史与现实 的逻辑。长期以来,欧洲医疗器械企业在中国市场享受到了高度的开放红利,深度参与中国医疗体系的 现代化进程,取得了显著发展。欧方6月2日的决定未能充分考虑这一背景,将对中欧多年来在医疗领域 积累的互信与合作基础造成冲击。 【环球时报报道 记者 倪浩】英国《金融时报》2日报道称,欧盟成员国投票决定,依据《国际采购工 具》(IPI)限制中国医疗器材进口,以反制北京在公共采购中对外国制造商的所谓"歧视"。根据IPI, 中国企业未来5年将被禁止参与价值超过500万欧元的欧盟医疗器械公共招标项目。 欧盟中国商会2日发表声明,"对欧方这一决定深表失望,对欧方将限制中企参与欧洲当地医疗采购市场 表示严重关切"。欧盟中国商会指出,IPI是欧方的单边工具,欧方这 ...
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Globenewswire· 2025-05-08 12:00
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in Q3 2025Strengthened leadership team with key appointments of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, ...